Providers should incorporate discussion of dietary supplements into patient counseling, Kevin Koo, MD, MPH, MPhil, advises.
Modest hypofractionation is noninferior to conventional fractionation in the treatment of localized prostate cancer and causes no increase in side effects, according to 8-year outcomes from the CHHiP trial.
Inheriting the adrenal-permissive HSD3B1(1245C) genotype is associated with worse outcomes in low-volume metastatic prostate cancer and might someday help identify patients who could benefit from escalated therapy, according to a recent study.
“We’re in an era of more personalized or precision medicine, and the ability to target cancer treatment to a patient’s specific genetic mutation or biomarker is becoming the standard,” according to Richard Pazdur, MD.
Overcoming challenges of medical therapy starts with leveraging guidelines.
Researchers studying a novel multimodal analgesia protocol at multiple institutions in the U.S. for patients having penile implant surgery found narcotic prescriptions before, during, and in the post-surgery recovery period fell from as high as 50 to 60 narcotic pills to 10 to 15 pills.
Two pharmaceuticals in late-stage development may offer new therapeutic options for patients with rare forms of hyperoxaluria.
“I think [MRI-guided transurethral ultrasound ablation] is a potentially great option for patients who opt for either whole- or partial-gland treatment,” says researcher Steven S. Raman, MD.
Myovant Sciences recently announced positive phase III trial results for its once-daily oral small molecule gonadotropin-releasing hormone antagonist relugolix, for the treatment of advanced prostate cancer.
Urologists, oncologists, and prostate cancer patients are entering a new era in prostate cancer therapy—one that is going to be genetically defined.